Children

Haemophilia A is commonly diagnosed at a young age, with severe haemophilia A often identified in the days following birth. During childhood, a highly effective, reliable treatment is essential.1

The World Federation of Hemophilia Guidelines highlight the importance of prophylaxis for children for the reduction of bleeding episodes.2 Prophylaxis is important for long-term health,2 as starting prophylaxis early has been shown to limit joint damage later in life.3

The efficacy of Nuwiq® (simoctocog alfa) has been demonstrated in prospective clinical trials in children of all ages with an established safety and tolerability profile.4,5

simoctocog-img

All-round efficacy of Nuwiq® (simoctocog alfa)

has been demonstrated in prospective clinical trials in children of all ages

Efficacy of prophylaxis with Nuwiq® in children

In previously treated children who
received long-term Nuwiq® prophylaxis for
a median of 2 years4
Median annualised bleeding rate
(ABR) for spontaneous bleeds
(n=47)
Had a dosing frequency of ≤2x/week
(n=33)
In previously untreated
children on continuous Nuwiq®
prophylaxis for ≥6 months5
Median ABR for
spontaneous bleeds
(n=50)
of 305 bleed treatments were rated as
excellent or good in children treated
with Nuwiq®6
In previously treated children
undergoing surgery, all 21 rated
surgeries were managed
successfully6
Efficacy was rated “excellent” for all
procedures with documented
efficacy assessments
In previously treated children who
received long-term Nuwiq® prophylaxis for
a median of 2 years4
Median annualised bleeding rate
(ABR) for spontaneous bleeds
(n=47)
Had a dosing frequency of ≤2x/week
(n=33)
In previously untreated
children on continuous Nuwiq®
prophylaxis for ≥6 months5
Median ABR for
spontaneous bleeds
(n=50)
of 305 bleed treatments were rated as
excellent or good in children treated
with Nuwiq®6
In previously treated children
undergoing surgery, all 21 rated
surgeries were managed
successfully6
Efficacy was rated “excellent” for all
procedures with documented
efficacy assessments

Nuwiq® in children

Early steps in life’s journey for people with severe haemophilia A

View publication

Nuwiq® safety and tolerability profile

is well-established in children

in children who received long-term Nuwiq® prophylaxis for a median of 2 years and as considered by the investigators4

in clinical trials with Nuwiq® in children6,7

reported in previously treated children who switched to Nuwiq® 6,8

References

  • 1

    Bertamino M et al. J Clin Med 2017; 6:54;​

  • 2

    Srivastava A et al. Haemophilia 2020; 26(Suppl. 6):1-158;​

  • 3

    Manco-Johnson MJ et al. N Engl J Med 2007; 357:535-44;​

  • 4

    Mathias M et al. Haemophilia 2023; 29:1005-12;​

  • 5

    Liesner RJ and Neufeld EJ. Blood 2019; 134(Suppl.1):903;​

  • 6

    Klukowska A et al. Haemophilia 2018; 24:595-603;​

  • 7

    Klukowska A et al. Ther Adv Hematol 2024; 15:20406207241245511;​

  • 8

    Lissitchkov T et al. Ther Adv Hematol 2019; 10:2040620719858471.

Drug safety related information should be reported to at1safetyinformation@octapharma.com If you are a patient, please contact your physician in case of adverse reactions. Please consider the pharmacovigilance data privacy statement if you are reporting drug safety relevant events.

This website is for healthcare professionals only.